TrialBMJ open2016

European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.

Olga Meulenbroek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.